[HTML][HTML] Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention

S Mirzaei, MDA Paskeh, E Okina, MH Gholami… - Journal of Experimental …, 2022 - Springer
Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …

Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics

M Adamaki, V Zoumpourlis - Pharmacology & therapeutics, 2021 - Elsevier
Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Administering [177Lu] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 …

RS Eapen, JP Buteau, P Jackson, C Mitchell, SF Oon… - European Urology, 2024 - Elsevier
Background High-risk localised prostate cancer (HRCaP) has high rates of biochemical
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …

[HTML][HTML] Role of natural and synthetic compounds in modulating NRF2/KEAP1 signaling pathway in prostate cancer

G Tossetta, S Fantone, D Marzioni, R Mazzucchelli - Cancers, 2023 - mdpi.com
Simple Summary Several studies showed that oxidative stress is involved in cancer
occurrence, development, progression chemoresistance and radio resistance. The nuclear …

Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells

Y Zhang, L He, A Sadagopan, T Ma, G Dotti… - Molecular cancer …, 2021 - AACR
Radiotherapy (RT) is a key treatment for prostate cancer. However, RT resistance can
contribute to treatment failure. Prostate cancer stem cells (PCSCs) are radioresistant. We …

mCRPC patients receiving 225Ac-PSMA-617 therapy in the post–androgen deprivation therapy setting: response to treatment and survival analysis

M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2022 - Soc Nuclear Med
225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is
overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in …

[HTML][HTML] Biological adaptations of tumor cells to radiation therapy

A Carlos-Reyes, MA Muñiz-Lino… - Frontiers in …, 2021 - frontiersin.org
Radiation therapy has been used worldwide for many decades as a therapeutic regimen for
the treatment of different types of cancer. Just over 50% of cancer patients are treated with …

EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways

M Rajput, R Singh, N Singh, RP Singh - Life Sciences, 2021 - Elsevier
Aim To study the role of EGFR signaling in regulation of intrinsic resistance in prostate
cancer. Materials and methods Radioresistant prostate carcinoma DU145 and PC-3 cells …

Hydroxychloroquine-loaded hollow mesoporous silica nanoparticles for enhanced autophagy inhibition and radiation therapy

Y Li, MH Cho, SS Lee, DE Lee, H Cheong… - Journal of controlled …, 2020 - Elsevier
Radiotherapy (RT) is a major modality for cancer treatment, along with surgery and
chemotherapy. Despite its therapeutic effect, the recurrence and metastasis of tumors due to …

[HTML][HTML] Cell plasticity and prostate cancer: The role of epithelial–mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance

S Papanikolaou, A Vourda, S Syggelos, K Gyftopoulos - Cancers, 2021 - mdpi.com
Simple Summary Although epithelial-to-mesenchymal transition (EMT) is a well-known
cellular process involved during normal embryogenesis and wound healing, it also has a …